These are the stocks that short sellers are betting against even as the market rallies
These stocks could fall and prove the hedge funds right, or rise and become potential short squeeze candidates. Source link
Read More
Madrigal Pharmaceuticals Inc
Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming
Drugmakers are racing to catch up to Madrigal Pharmaceuticals, which has the first drug for NASH liver disease. Meanwhile, AI
Read More
FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
The FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are
Read More
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might
Read More
Traders who bet against stocks made a killing in 2022, as short sellers netted $300 billion
Short holdings had a return of 30.8% in 2022 as the market slid. Source link
Read More